Rituximab, also known by its brand name Rituxan, is a type of monoclonal antibody used primarily in the treatment of various types of cancer, particularly lymphomas and leukemias. It targets the CD20 antigen found on the surface of B-cells, which are a type of white blood cell involved in the immune response.
